David Nierengarten


ANALYST BIOGRAPHY

David Nierengarten, Ph.D., has been a senior analyst covering small-mid cap biotech stocks with a heavy focus on oncology, rare disease and gene therapy. His prior experience in venture capital and operations at a private biotechnology company, helps him succeed in analyzing both science and business models. In addition, David has results in predicting Dendreon’s looming bankruptcy, and several M&A events involving NPS Pharmaceuticals and Anacor.

David received his B.S. in Biochemistry from the University of Wisconsin-Madison, and Ph.D. in Molecular and Cell Biology from the University of California at Berkeley.

ANALYST EDGE

David’s Edge: His early state venture capital investing experience makes him well rounded, and can be found as a resource for M&A, and IPO trends for small/mid cap biotechs. With his primary focus being clinical trials in oncology, he understands the complexities of gene therapy, and can explain the risk/reward scenarios for developing-stage biotechnology companies. Combing both experiences provides him insights for corporate operations that have helped him generate value creation in this event-driven space.

COMPANIES UNDER COVERAGE

  • AnaptysBio, Inc. (ANAB)
  • Applied Genetic Technologies Corp (AGTC)
  • arGEN-X SE (ARGX)
  • AVROBIO, Inc. (AVRO US)
  • bluebird bio (BLUE)
  • Blueprint Medicines Corp (BPMC)
  • Chimerix Inc. (CMRX)
  • Codiak BioSciences (CDAK)
  • Epizyme Inc. (EPZM)
  • Fate Therapeutics (FATE)
  • Fennec Pharma (FENC)
  • Freeline TherapeuticesHoldings PLC (FRLN)
  • Fusion Pharmaceuticals (FUSN)
  • G1 Therapeutics Inc. (GTHX)
  • Generation Bio Co (GBIO)
  • Intellia Therapeutics (NTLA)
  • Inozyme Pharma (INZY)
  • iTeos Therapeutics Inc. (ITOS)
  • Iveric Bio Inc. (ISEE)
  • Karyopharm Therapeutics (KPTI)
  • Kiniksa Pharmaceuticals (KNSA)
  • Kinnate Biopharma (KNTE)
  • MacroGenics (MGNX)
  • Magenta Therapeutics (MGTA)
  • Mersana Therapeutics (MRSN)
  • MyoKardia Inc. (MYOK)
  • NovoCure Ltd. (NVCR)
  • Nuvation Bio (NUVB)
  • Orchard Therapeutics (ORTX)
  • Scholar Rock (SRRK)
  • Springworks Therapeutics Inc. (SWTX)
  • Sutro Biopharma (STRO)
  • TCR2 Therapeutics Inc. (TCRR)
  • Turning Point Inc (TPTX)
  • Xencor (XNCR)
  • Y-mAbs Therapeutics, Inc. (YMAB)